Current research projects
Genetic determinants of lipidomic variation and their role in CVD risk
Aims to enhance our understanding of genetic factors contributing to cardiovascular disease (CVD), the world's leading cause of death. Through the analysis of the long-running Busselton Health Study and its large family lineages, researchers aim to identify and validate rare causal variants for CVD. This comprehensive project employs Whole Genome Sequencing and targeted lipidomic profiling to not only gain new insights into CVD risk factors but also evaluate the clinical utility of these findings in familial hypercholesterolemia, a common cause of high cholesterol. This project may contribute significantly to the field by introducing novel methods for CVD risk prediction and management.
Identifying novel lipid and genetic signatures of metabolic disease in early childhood
Explores the early origins of metabolic diseases, hypothesising that combined plasma lipidomic and genomic profiles can help identify individuals at risk. This project utilises two unique, well-established birth cohorts from Singapore and Australia to examine genetic risk factors and environmental exposures during early childhood. The project aims to shed light on early markers of metabolic diseases and the potential for preventive interventions, thereby potentially altering adverse health trajectories at an early age.
Lipidomic analysis of Alzheimer’s disease: biology, risk assessment and early diagnosis
Seeks to understand the links between lipid metabolism and the onset and progression of Alzheimer's disease (AD). Leveraging lipidomic studies of the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing cohort, this project has identified several lipid species associated with AD and its progression. By analysing platelet samples and validating their findings on independent cohorts, researchers aim to refine predictive models, validate lipidomic biomarkers, and assess the risk of AD. The project aims to provide new therapeutic targets for early intervention to halt the onset and progression of AD.